The Vanguard Study

Looking Toward the Future of Early Cancer Detection

Medical breakthroughs begin with research—and the Vanguard Study is one of the most promising cancer screening studies underway today.

Sponsored by the National Cancer Institute (NCI), the Vanguard Study officially began on June 18, 2025, and is evaluating whether new multi-cancer detection (MCD) blood tests can identify several cancers before symptoms appear.

Researchers hope these innovative blood tests could one day become an additional screening tool that complements today's standard cancer screening methods.

While the results are still years away, studies like Vanguard represent an exciting step toward improving early detection and saving more lives.

1. What Is the Vanguard Study?

The Vanguard Study is one of the nation's largest clinical trials focused on early cancer detection.

Researchers plan to enroll approximately 24,000 adults between the ages of 45 and 75 who do not currently have cancer.

Participants receive either one of two multi-cancer blood tests or standard medical care, allowing researchers to compare how well these tests perform over time.

The study is expected to continue through 2029.

1.1 Why Is This Study Important?

Many cancers produce few or no symptoms during their earliest stages.

Finding cancer earlier often means:

• More treatment options

• Less aggressive treatment

• Better survival rates

• Improved quality of life

Researchers hope the Vanguard Study will determine whether blood-based screening can help detect cancers earlier without creating unnecessary testing or anxiety.

1.2 Which Cancers Could Be Detected?

The blood tests being studied may detect signals associated with multiple cancers, including:

• Prostate Cancer

• Breast Cancer

• Lung Cancer

• Colorectal Cancer

• Pancreatic Cancer

• Ovarian Cancer

• Liver Cancer

• Bladder Cancer

• Esophageal Cancer

• Stomach Cancer

Researchers are evaluating how accurately these tests identify each cancer while reducing false positives.

2. What Does This Mean for Prostate Cancer?

The Vanguard Study represents exciting progress, but it does not replace PSA screening.

Today, PSA testing remains one of the most effective tools for identifying prostate cancer early.

Men should continue talking with their healthcare provider about screening based on:

• Age

• Family history

• Race and ethnicity

• Personal risk factors

Until future research proves otherwise, PSA testing continues to play a critical role in early detection.

2.1 Why Curt Cares Is Following This Research

At Curt Cares, our mission is to educate, advocate, and encourage meaningful conversations about men's health.

The Vanguard Study is an excellent example of how research continues moving healthcare forward.

While scientists explore tomorrow's technologies, our message remains the same:

Know your risk.

Talk with your healthcare provider.

Don't delay recommended screenings.

3. Looking Ahead

The Vanguard Study reminds us that the future of cancer detection is evolving rapidly.

Research, innovation, and clinical trials continue to improve how cancer is found and treated.

At Curt Cares, we'll continue following important medical advances while encouraging men and their families to focus on what they can do today—have the conversation, understand their risk, and get screened when appropriate.

Curt Cares Perspective

Every breakthrough begins with research.

Every life saved begins with awareness.

And every conversation has the power to change a future.

Start the conversation. Get screened. Stay informed.

Source

National Cancer Institute (NCI) – Vanguard Study
ClinicalTrials.gov Identifier: NCT06995898